Plain-English translation of NCT05717790 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether adding , a new type of antibody medication, to standard chemotherapy and radiation therapy works better than chemotherapy and radiation alone for advanced nasopharyngeal cancer (cancer in the upper throat behind the nose). works by targeting a protein on cancer cells called EGFR, which may help slow or stop cancer growth. The study will enroll 288 patients to compare how well this combination treatment works and how safe it is.
Advanced nasopharyngeal cancer is difficult to treat and has high rates of recurrence. This medication targets a specific protein on cancer cells that is often overactive in this type of cancer, and researchers believe adding it to standard chemotherapy and radiation might improve survival rates and help prevent the cancer from coming back.
You likely qualify if…
You likely don't qualify if…
If you join the experimental group, you will receive weekly injections of the medication plus chemotherapy drugs (given intravenously) for 2 cycles before starting radiation. Then you will receive daily radiation therapy for 6–7 weeks while continuing weekly injections of the medication and chemotherapy every 3 weeks. After radiation ends, you will receive injections of the medication alone every 3 weeks for 8 cycles (about 6 months). If you are in the comparison group, you will receive the same chemotherapy and radiation schedule, but without the initial medication phase before radiation, though you will still receive it during radiation. Throughout treatment, you will have regular blood tests and imaging scans to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China